The administration said the update to the dashboards is part of its effort to improve transparency around drug pricing; the administration also wants to shift some Part B coverage to Part D as part of its plan to reduce total drug spending, with the idea that Part D plan sponsors would have more negotiating room with pharmaceutical companies.
CMS recently updated its drug spending dashboards with data for 2017, displaying pricing and spending data for thousands of drugs across Medicare Parts B and D and Medicaid.
In 2017, total gross spending on prescription drugs was $154.9 billion in Medicare Part D, $30.4 billion in Part B, and $67.6 billion in Medicaid.
The drug dashboards last updated in May of last year. The administration said it is part of its effort to improve transparency around drug pricing; the administration also wants to shift some Part B coverage to Part D as part of its plan to reduce total drug spending, with the idea that Part D plan sponsors would have more negotiating room with pharmaceutical companies.
The dashboards focus on average spending per dosage unit for prescription drugs and track the change in average spending per dosage unit over time. The web-based tool (or the downloadable spreadsheet, which has more information) can be sorted by manufacturer, drug, price, and more.
“The dashboards pinpoint the sources of rising prescription drug prices to help guide our continued work to address this problem,” said CMS Administrator Seema Verma. She said that, from 2013-2017, prescription drug spending grew at an average annual rate of 10.6% in Medicare Part D, 10% in Part B, and 14.8% in Medicaid.
Verma said in her statement that the tool could be used, for instance, to help doctors and patients compare prices.
However, while the CMS spreadsheets include the number of manufacturers available for a given drug, they do not indicate whether a biosimilar is available for brand-name biologics.
Some of the cost increases for brand-name biologic products include the following:
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.